Improvement of overall survival in stage IV melanoma patients during 2011-2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR).

Date publication

mars 2017

Journal

Journal of cancer research and clinical oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr AMARAL Teresa Maria

Tous les auteurs :
Forschner A, Eichner F, Amaral T, Keim U, Garbe C, Eigentler TK

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27878363

Résumé

During 2011 and 2014, new treatment modalities like tyrosine kinase inhibitors and checkpoint inhibitors were introduced into the therapy of metastatic melanoma. This study addresses the question whether overall survival (OS) of metastatic melanoma patients has already been improved in 441 patients diagnosed with metastatic melanoma between 2011 and 2014 in the real-world setting at the University Hospital Tuebingen.

Mots clés

Brain metastasis, Checkpoint inhibitors, Chemotherapy, Ipilimumab, Melanoma, Nivolumab, Pembrolizumab, Survival, Targeted therapy

Référence

J Cancer Res Clin Oncol. 2017 03;143(3):533-540